Sheila Nina Balinda is an Assistant Professor/Principal
Research Scientist (molecular virologist) at the Medical Research Council/Uganda
Virus Research Institute (MRC/UVRI) and London School of Hygiene & Tropical
Medicine (LSHTM) Uganda Research Unit. She received a B.Sc. in biochemistry
(2001) and a Ph.D. in molecular virology (2011) from Makerere University
(Uganda), and an M.Sc. in applied molecular microbiology (2005) from Nottingham
University (UK). She has extensive experience in “One Health”, having studied
both animal (foot and mouth disease, FMD) and human (HIV) viruses for over 15
years. She leads a team of Ugandan researchers working with a novel adenovector
platform for COVID-19 and CCHF vaccine development funded by the governments of
Uganda and Britain, respectively. She is currently part of the virus
surveillance team that will inform priority immunogens for vaccine development
and bnAB prevention approaches targeted to specific populations in Africa and
India.
Sheila Nina Balinda is an Assistant Professor/Principal
Research Scientist (molecular virologist) at the Medical Research Council/Uganda
Virus Research Institute (MRC/UVRI) and London School of Hygiene & Tropical
Medicine (LSHTM) Uganda Research Unit. She received a B.Sc. in biochemistry
(2001) and a Ph.D. in molecular virology (2011) from Makerere University
(Uganda), and an M.Sc. in applied molecular microbiology (2005) from Nottingham
University (UK). She has extensive experience in “One Health”, having studied
both animal (foot and mouth disease, FMD) and human (HIV) viruses for over 15
years. She leads a team of Ugandan researchers working with a novel adenovector
platform for COVID-19 and CCHF vaccine development funded by the governments of
Uganda and Britain, respectively. She is currently part of the virus
surveillance team that will inform priority immunogens for vaccine development
and bnAB prevention approaches targeted to specific populations in Africa and
India.